News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|December 9, 2024

NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Author(s)Michael Levy, MD, PhD

Key Takeaways

Early and aggressive treatment strategies are crucial in reducing NMOSD relapse and hospitalization rates.
Personalized treatment plans should incorporate new therapeutic agents and monitoring protocols for optimal outcomes.
Collaboration with multidisciplinary teams and patient education are essential in effective NMOSD management.
Sharing insights and experiences with peers enhances understanding and implementation of management strategies.

SHOW MORE

A panelist discusses how neurologists can adapt their NMOSD management strategies based on recent findings about relapse and hospitalization rates, sharing practical advice and clinical experience for optimizing patient outcomes.

Episodes in this series

Michael Levy, MD, PhD, is featured in this series.

EP. 1 Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Michael Levy, MD, PhD, is featured in this series.

EP. 2 Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

Michael Levy, MD, PhD, is featured in this series.

EP. 3 Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management

Michael Levy, MD, PhD, is featured in this series.

EP. 4 NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Video content above is prompted by the following:

In your clinical practice, how have you adapted your approach to NMOSD management in light of these recent findings on relapse and hospitalization rates?
What advice do you have for other neurologists in managing patients with NMOSD and reducing relapse/hospitalization rates?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

A Call for Greater Education in Stem Cell Therapies

ByMarco Meglio,Claire Henchcliffe, MD, DPhil,Roger A. Barker, MD, PhD

June 6th 2026

SKY-0515 Reduces mHTT, Alexion C5 inhibitors Reduces Relapse Rate, Exploring Stem Cell Innovation in PD

ByNeurologyLive® Staff

June 6th 2026

NeurologyLive® Friday 5 — June 5, 2026

ByIsabella Ciccone, MPH

June 5th 2026

Anti-PACAP Antibody Bocunebart Meets Primary Endpoint in Phase 2b Migraine Prevention Trial

June 5th 2026

Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD

ByJohn Corboy, MD,Isabella Ciccone, MPH

June 5th 2026

Latest CME

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD

Stem Cell Therapy Versus Traditional Parkinson Treatments

What Clinicians Need to Know About Emerging Stem Cell Therapies for Parkinson Disease

NeurologyLive® Friday 5 — June 5, 2026

Anti-PACAP Antibody Bocunebart Meets Primary Endpoint in Phase 2b Migraine Prevention Trial